Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of “Buy” by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned a consensus rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued a report on the stock in the last year is $29.50.

A number of brokerages recently issued reports on CPRX. HC Wainwright boosted their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup raised their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $21.16 on Friday. The company’s 50 day moving average price is $20.08 and its 200-day moving average price is $17.32. Catalyst Pharmaceuticals has a 52-week low of $11.89 and a 52-week high of $21.85. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 39.19, a P/E/G ratio of 3.18 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. The business had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. As a group, equities research analysts forecast that Catalyst Pharmaceuticals will post 1.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares in the company, valued at approximately $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the sale, the insider now owns 12,369 shares in the company, valued at approximately $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at $7,012,367.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 201,058 shares of company stock valued at $4,018,188 over the last ninety days. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CPRX. Oppenheimer & Co. Inc. bought a new position in shares of Catalyst Pharmaceuticals during the first quarter valued at $805,000. Sei Investments Co. grew its position in Catalyst Pharmaceuticals by 64.3% during the 1st quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 32,621 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Catalyst Pharmaceuticals during the 1st quarter valued at about $954,000. Vanguard Group Inc. raised its holdings in Catalyst Pharmaceuticals by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company’s stock worth $119,694,000 after buying an additional 73,930 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Catalyst Pharmaceuticals in the second quarter worth approximately $258,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.